Peer-influenced content. Sources you trust. No registration required. This is HCN.
On May 31, 2020, at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Sessions, late-breaking data dropped for three potentially practice-changing studies: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.
Hematology June 1st 2020
In this Special Report, the American Society of Clinical Oncology (ASCO) publishes guidance for oncology practices on how to safely restore patient access to diagnostics, treatments, and other critical cancer care services.
Internal Medicine May 25th 2020
The New England Journal of Medicine
In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors.
Gastroenterology May 18th 2020
Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.
Hematology May 18th 2020
This roundup of articles highlights the 14 vaccines doctors are targeting in the fight against COVID‑19, in addition to featuring one doctor’s claim that the virus was active in France in December 2019, almost a month earlier than previously believed.
Allergy & Immunology May 11th 2020
According to a study featured in the Journal of Clinical Oncology, pre-surgery letrozole led to significant imaging and biomarker changes in postmenopausal patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) in a phase 2 clinical trial.
Internal Medicine May 11th 2020